CN1330548A - 用作抗动脉粥样硬化剂的原花色素a2的磷脂复合物 - Google Patents
用作抗动脉粥样硬化剂的原花色素a2的磷脂复合物 Download PDFInfo
- Publication number
- CN1330548A CN1330548A CN99814446A CN99814446A CN1330548A CN 1330548 A CN1330548 A CN 1330548A CN 99814446 A CN99814446 A CN 99814446A CN 99814446 A CN99814446 A CN 99814446A CN 1330548 A CN1330548 A CN 1330548A
- Authority
- CN
- China
- Prior art keywords
- proanthocyanidin
- complex
- phospholipid
- medicine
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NSEWTSAADLNHNH-TXZJYACMSA-N Proanthocyanidin A-2 Natural products C1([C@H]2OC3=C4[C@H]5C6=C(O)C=C(O)C=C6O[C@]([C@@H]5O)(OC4=CC(O)=C3C[C@@H]2O)C=2C=C(O)C(O)=CC=2)=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-TXZJYACMSA-N 0.000 title claims abstract description 23
- 229920002982 Procyanidin A2 Polymers 0.000 title claims abstract description 23
- NSEWTSAADLNHNH-UHFFFAOYSA-N pavetannin A-2 Natural products OC1CC2=C(O)C=C3OC(C4O)(C=5C=C(O)C(O)=CC=5)OC5=CC(O)=CC(O)=C5C4C3=C2OC1C1=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-UHFFFAOYSA-N 0.000 title claims abstract description 23
- NSEWTSAADLNHNH-LSBOWGMISA-N proanthocyanidin A2 Chemical compound C1([C@H]2OC3=C4[C@H]5C6=C(O)C=C(O)C=C6O[C@]([C@@H]5O)(OC4=CC(O)=C3C[C@H]2O)C=2C=C(O)C(O)=CC=2)=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-LSBOWGMISA-N 0.000 title claims abstract description 23
- 150000003904 phospholipids Chemical class 0.000 title claims abstract description 9
- 230000000879 anti-atherosclerotic effect Effects 0.000 title description 2
- 239000003814 drug Substances 0.000 claims description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract description 2
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 208000035150 Hypercholesterolemia Diseases 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000001715 carotid artery Anatomy 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000021395 porridge Nutrition 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- PRYIJAGAEJZDBO-ZEQHCUNVSA-N 5,6alpha-epoxy-5alpha-cholestan-3beta-ol Chemical compound C([C@]12O[C@H]1C1)[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 PRYIJAGAEJZDBO-ZEQHCUNVSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 229920001991 Proanthocyanidin Polymers 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000001643 venotonic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
用于预防和治疗由动脉粥样硬化引起的病症的原花色素A2的磷脂复合物。
Description
本发明涉及原花色素A2或富含原花色素A2的提取物的磷脂复合物及其在制备用于预防和治疗动脉粥样硬化、心肌梗塞和脑梗塞的药物中的应用。
原花色素A2或式(I)的8，14-桥亚甲基-2H，14H-1-苯并吡喃并[7，8-d][1，3]苯并二氧杂环辛烷-3，5，11，13，15-戊醇-2，8-二(3，4-二羟基苯基)-3，4-二氢[2R-2α，3α，8β，14β，15R]
是从马栗树种子中分离出来的(Tetrahedron Lett.，429，1966)。EP-A-210785(1987年2月4日)公开了原花色素A2作为结瘢剂、细胞保护剂、抗溃疡剂、静脉紧张剂(venotonic)、血管保护剂和抗过氧化剂的治疗应用。
现在已经惊奇地发现，当系统给药、优选通过口服途径给药时，原花色素A2的磷脂复合物在动物和人中表现出显著的抗动脉粥样硬化活性。
本发明复合物可由天然或合成磷脂，例如卵磷脂、磷脂酰胆碱、磷脂酰丝氨酸、磷脂酰乙醇胺组成。原花色素A2与磷脂的比例为2∶1-1∶2、优选为约1∶1.5w/w。特别优选的复合物是与大豆磷脂酰胆碱的复合物。
本发明复合物是这样制得的：将磷脂溶液与原花色素A2在合适的溶剂例如丙酮、乙酸乙酯、乙醇中的溶液反应，然后将该反应混合物减压浓缩，获得了浓稠的残余物，可将残余物磨碎。
本发明复合物剂量依赖性地阻止或减轻动脉粥样斑块的形成。该活性在喂高胆固醇食物以在血管水平、特别是主动脉弓、腹主动脉、颈动脉和脑血管水平上诱导出与人类似的动脉粥样损害的兔子中得到了证实。在所述模型中，与未治疗动物相比，上述磷脂复合物改变了宏观和微观的血管状况，使得动脉粥样化斑的数量和严重程度都降低了，带来了令人惊奇的血管组织方面的益处。在关于脑保护的另一动脉粥样硬化模型中，通过手术减小兔子内颈动脉的血管腔，同时施用富含饱和脂肪的高胆固醇血饮食，在施用本发明复合物后，我们观察到，颈动脉堵塞减轻了，血管壁厚度变薄了，并且动物存活率提高了。6个月的治疗后，动脉粥样硬化患者表现出，由于动脉粥样化斑造成的颈动脉堵塞减轻了，并且改善了颈动脉血流(通过多普勒超声波检查法测定的)。
原花色素A2的磷脂复合物可以以合适的口服给药剂型例如片剂、软或硬明胶胶囊剂使用，根据疾病的严重程度，其每天以50到500mg的剂量给药2-3次。可依据常规技术和赋形剂制备药物制剂。
下述实施例更详细地举例说明本发明。
实施例1制备原花色素A2与磷脂的复合物
在70℃，将1kg原花色素A2在5升丙酮中的溶液加到1577g磷脂酰胆碱在5升乙酸乙酯中的溶液中。
将该混合物在搅拌下回流，然后真空蒸发至干。将所得残余物在50℃真空干燥24小时，然后研磨以获得具有所需粒径的颗粒。
实施例2
将32只新西兰兔子分成4组，每组有8只兔子，并如下所述进行治疗：组1)：对照组，标准饮食组2)：高胆固醇血饮食(0.2％w/w胆固醇)组3)：高胆固醇血饮食＋原花色素A2提取物的磷脂复合物(0.2％胆固醇+2％w/w实施例1的复合物)组4)：高胆固醇血饮食＋原花色素A2提取物(0.2％胆固醇＋原花色素A2，后者的量相当于在2％w/w实施例1复合物中存在的量)。
8周治疗后，将动物杀死，在治疗期间测定胆固醇、LDL/VLDL、HDL和甘油三酯水平。
测定在胸和腹部主动脉上的动脉粥样损害的数目、大小和分布。
将主动脉条固定，并用苏丹IV染色，以目测检验损害，并通过气相色谱法测定血管胆固醇和氧化胆固醇的含量。
在下表中报告的结果证实了用原花色素A2的磷脂复合物进行治疗使得由高胆固醇血饮食引起的动脉粥样损害以统计学显著的方式减轻。
表治疗 损害的面积％组 0.5％组2 34％组3 7.5％*组4 30％*与组2相比，p＜0.01。
实施例3含有500mg原花色素A2的磷脂复合物的胶囊组成：原花色素A2与大豆磷脂酰胆碱的复合物 150mg乳糖 57mg改性淀粉 40mg硬脂酸镁 3.0mg
实施例4胃耐受性片剂原花色素A2与大豆磷脂酰胆碱的复合物 200mg微晶纤维素 118mg沉淀二氧化硅 3mg硬脂酸镁 4mg异丁烯酸阴离子聚合物及其酯 12mg滑石粉 8mg碳酸镁 8mg玉米淀粉 5mg阿拉伯树胶 159mg
实施例5软明胶胶囊原花色素A2与大豆磷脂酰胆碱的复合物 216mg花生油 209mg部分氢化植物油 100mg大豆卵磷脂 5mg
Claims (9)
1.原花色素A2或富含原花色素A2的提取物的磷脂复合物。
2.权利要求1的复合物，其中所述磷脂选自卵磷脂、磷脂酰胆碱、磷脂酰乙醇胺、磷脂酰丝氨酸。
3.权利要求2的复合物，其中所述磷脂是磷脂酰胆碱。
4.权利要求1-3任一项的复合物，其中原花色素A2与磷脂的重量比为2∶1-1∶2。
5.权利要求1-4的复合物在制备用于预防或治疗动脉粥样硬化、心肌梗塞和脑梗塞的药物中的应用。
6.权利要求5的应用，其中所述药物的单位剂量为50-500mg活性组分。
7.权利要求5或6的应用，其中所述药物是通过口服途径给药的。
8.权利要求7的应用，其中所述药物呈软或硬明胶胶囊剂或片剂形式。
9.含有权利要求1-4复合物作为活性组分的药物组合物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI98A002732 | 1998-12-18 | ||
| IT1998MI002732A IT1304183B1 (it) | 1998-12-18 | 1998-12-18 | Complessi di proantocianidina a2 con fosfolipidi come agentiantiaterosclerotici. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1330548A true CN1330548A (zh) | 2002-01-09 |
| CN1146429C CN1146429C (zh) | 2004-04-21 |
Family
ID=11381268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB998144460A Expired - Fee Related CN1146429C (zh) | 1998-12-18 | 1999-12-13 | 用作抗动脉粥样硬化剂的原花色素a2的磷脂复合物 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6429202B1 (zh) |
| EP (1) | EP1140115B1 (zh) |
| JP (1) | JP4842436B2 (zh) |
| KR (1) | KR100694907B1 (zh) |
| CN (1) | CN1146429C (zh) |
| AT (1) | ATE238803T1 (zh) |
| AU (1) | AU763907B2 (zh) |
| CA (1) | CA2355776C (zh) |
| CZ (1) | CZ301495B6 (zh) |
| DE (1) | DE69907509T2 (zh) |
| DK (1) | DK1140115T3 (zh) |
| ES (1) | ES2197708T3 (zh) |
| HK (1) | HK1042430B (zh) |
| HU (1) | HU228928B1 (zh) |
| IL (2) | IL143751A0 (zh) |
| IT (1) | IT1304183B1 (zh) |
| NO (1) | NO328733B1 (zh) |
| PL (1) | PL197153B1 (zh) |
| PT (1) | PT1140115E (zh) |
| RU (1) | RU2248798C2 (zh) |
| SK (1) | SK284884B6 (zh) |
| WO (1) | WO2000037062A2 (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102688501A (zh) * | 2012-06-20 | 2012-09-26 | 浙江萧山医院 | 原花青素b2磷脂复合物及其制备方法和用途 |
| CN103467778A (zh) * | 2013-09-06 | 2013-12-25 | 天津大学 | 细菌纤维素/卵磷脂复合材料及制备和应用 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8507018B2 (en) * | 1998-03-12 | 2013-08-13 | Mars, Incorporated | Products containing polyphenol(s) and L-arginine and methods of use thereof |
| EP1482920B2 (en) * | 2002-02-12 | 2011-07-20 | Hunza di Pistolesi Elvira & C. S.a.S. | Compositions containing n-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids |
| ITMI20020756A1 (it) * | 2002-04-09 | 2003-10-09 | Sinclair Pharma S R L | Composizioni farmaceutiche topiche per il trattamento delle dermatiti |
| GB0321996D0 (en) * | 2003-09-19 | 2003-10-22 | Novartis Nutrition Ag | Organic compounds |
| EP1713467B1 (en) * | 2004-01-28 | 2012-08-01 | Mars, Incorporated | Compositions and methods of use of a-type procyanidins |
| EP1837030A1 (en) | 2006-03-09 | 2007-09-26 | INDENA S.p.A. | Phospholipid complexes of curcumin having improved bioavailability |
| WO2009104556A1 (ja) * | 2008-02-19 | 2009-08-27 | 株式会社岐阜セラツク製造所 | 組成物 |
| IT1398624B1 (it) * | 2009-02-02 | 2013-03-08 | Dermogyn S R L | Uso cosmetico della proantocianidina a2 |
| RU2456674C1 (ru) * | 2011-05-31 | 2012-07-20 | Тагир Уралович Гафаров | Способ моделирования атрофического рубца кожи |
| CN103120798A (zh) * | 2013-01-10 | 2013-05-29 | 施冬云 | 一种具有抗氧化应激作用的磷脂复合物制备方法及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4698360B1 (en) | 1985-04-09 | 1997-11-04 | D Investigations Pharmacologiq | Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof |
| GB8518289D0 (en) * | 1985-07-19 | 1985-08-29 | Inverni Della Beffa Spa | Obtaining proanthocyanidine a2 |
| IT1201149B (it) * | 1987-01-14 | 1989-01-27 | Indena Spa | Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche |
| IT1201151B (it) * | 1987-01-14 | 1989-01-27 | Indena Spa | Complessi fosfolipidici con estratti da vitis vinifera,procedimento per la loro preparazione e composizioni che li cntengono |
| IT1265312B1 (it) * | 1993-12-21 | 1996-10-31 | Indena Spa | Formulazioni contenenti carotenoidi e procarotenoidi associati a polifenoli nella prevenzione dei danni da abnorme produzione di |
| US5648377A (en) | 1993-12-21 | 1997-07-15 | Indena S.P.A. | Formulations containing carotenoids an procarotenoids combined with polyphenols in the prevention of the damages due to an abnormal production of free radicals |
| IT1270999B (it) * | 1994-07-26 | 1997-05-26 | Indena Spa | Formulazioni a base di cumarine e loro uso in campo farmaceutico e cosmetico |
| FI955691A (fi) * | 1994-11-28 | 1996-05-29 | Suntory Ltd | Lipoproteiini(a):ta alentava aine, kolesterolia alentava aine ja näitä aineita sisältävät lääkkeet |
| IT1296920B1 (it) * | 1997-12-04 | 1999-08-03 | Indena Spa | Uso di complessi di estratti vitis vinifera con fosfolipidi come agenti anti-aterosclerotici |
| EP1210785B1 (de) | 1999-09-08 | 2005-11-23 | Siemens Aktiengesellschaft | Anordnung und verfahren für eine optische informationsübertragung |
-
1998
- 1998-12-18 IT IT1998MI002732A patent/IT1304183B1/it active
-
1999
- 1999-12-13 ES ES99966956T patent/ES2197708T3/es not_active Expired - Lifetime
- 1999-12-13 AT AT99966956T patent/ATE238803T1/de active
- 1999-12-13 US US09/857,804 patent/US6429202B1/en not_active Expired - Lifetime
- 1999-12-13 CN CNB998144460A patent/CN1146429C/zh not_active Expired - Fee Related
- 1999-12-13 RU RU2001116085/15A patent/RU2248798C2/ru not_active IP Right Cessation
- 1999-12-13 SK SK860-2001A patent/SK284884B6/sk not_active IP Right Cessation
- 1999-12-13 IL IL14375199A patent/IL143751A0/xx active IP Right Grant
- 1999-12-13 CA CA002355776A patent/CA2355776C/en not_active Expired - Fee Related
- 1999-12-13 KR KR1020017007374A patent/KR100694907B1/ko not_active IP Right Cessation
- 1999-12-13 DK DK99966956T patent/DK1140115T3/da active
- 1999-12-13 EP EP99966956A patent/EP1140115B1/en not_active Expired - Lifetime
- 1999-12-13 PL PL349534A patent/PL197153B1/pl unknown
- 1999-12-13 PT PT99966956T patent/PT1140115E/pt unknown
- 1999-12-13 DE DE69907509T patent/DE69907509T2/de not_active Expired - Lifetime
- 1999-12-13 CZ CZ20012134A patent/CZ301495B6/cs not_active IP Right Cessation
- 1999-12-13 HU HU0104665A patent/HU228928B1/hu not_active IP Right Cessation
- 1999-12-13 AU AU22830/00A patent/AU763907B2/en not_active Ceased
- 1999-12-13 WO PCT/EP1999/009854 patent/WO2000037062A2/en active IP Right Grant
- 1999-12-13 JP JP2000589173A patent/JP4842436B2/ja not_active Expired - Fee Related
-
2001
- 2001-06-13 IL IL143751A patent/IL143751A/en not_active IP Right Cessation
- 2001-06-14 NO NO20012944A patent/NO328733B1/no not_active IP Right Cessation
-
2002
- 2002-04-30 HK HK02103200.8A patent/HK1042430B/zh not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102688501A (zh) * | 2012-06-20 | 2012-09-26 | 浙江萧山医院 | 原花青素b2磷脂复合物及其制备方法和用途 |
| CN103467778A (zh) * | 2013-09-06 | 2013-12-25 | 天津大学 | 细菌纤维素/卵磷脂复合材料及制备和应用 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pawar et al. | Phytosome as a novel biomedicine: a microencapsulated drug delivery system | |
| JP3548102B2 (ja) | 高血圧症予防・治療剤 | |
| ES2340510T3 (es) | Uso de alquil-furanos para la preparacion de un medicamento destinado al tratamiento de la obesidad y para el tratamiento cosmetico del exceeso de peso. | |
| CN1330548A (zh) | 用作抗动脉粥样硬化剂的原花色素a2的磷脂复合物 | |
| US4910224A (en) | Method of modifying the lipid structure and function of cell membranes and pharmaceutical compositions for use therein | |
| TWI359667B (en) | Formulation for oral administration having a healt | |
| CN1126564C (zh) | 葡萄提取物的膦脂复合物作为抗动脉粥样硬化剂的应用 | |
| US6329000B1 (en) | Extract of pine needle and the use thereof | |
| AU2003222814B2 (en) | Pharmaceutical composition comprising a lipase inhibitor and glucomannan | |
| EP1090635B1 (en) | Use of ferulic acid for treating hypertension | |
| JP2009114101A (ja) | 歯周病の予防又は治療用の医薬組成物、口腔衛生剤、並びに食品組成物 | |
| CN109260214A (zh) | 芍药苷类化合物在制备治疗脓毒症药物中的应用 | |
| AU604226B2 (en) | Method of modifying the lipid structure function and expression of cell membranes and pharmaceutical compositions for use therein | |
| JP3024789B2 (ja) | 血圧降下剤 | |
| US3803319A (en) | Treating hyperlipemia with isatin | |
| JPH04230628A (ja) | 脂質調節薬としての１０員環ラクトンの使用 | |
| JPS5843385B2 (ja) | シジミの薬効成分及びその製造法 | |
| KR100838422B1 (ko) | 지방분해 촉진제 및 이를 함유하는 체중감량용 피부화장료, 음식품 조성물 및 그 작용에 기초하는 체중 감량 방법 | |
| JP3051375B2 (ja) | 共役リノール酸を有効成分とする抗アレルギー剤 | |
| KR20040036092A (ko) | 진세노사이드 Rh2 및 Rg3 항암 조성물 | |
| JP2023547111A (ja) | ガラクトースを含有する免疫過敏疾病の予防、改善、または治療用組成物 | |
| CN117398415A (zh) | 嗜黏蛋白阿克曼菌以及相关组合物在制备血管钙化抑制剂中的应用 | |
| GB2224206A (en) | Pharmaceutical compositions containing ace inhibitors. | |
| JP2000327571A (ja) | 抗かゆみ組成物 | |
| JPS58150513A (ja) | 血管壁代謝改善剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040421 Termination date: 20161213 |